1 INTRODUCTION
1.1 MARKET SEGMENTATION

2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF INSULIN PEN NEEDLES MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY
3.1 GLOBAL INSULIN PEN NEEDLES MARKET SNAPSHOT
3.2 GLOBAL INSULIN PEN NEEDLES MARKET REVENUE, 2017– 2025(US$ MN)

4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS

5 GLOBAL INSULIN PEN NEEDLES MARKET, BY TYPES
5.1 OVERVIEW
5.2 STANDARD INSULIN PEN NEEDLE
5.3 SAFETY INSULIN PEN NEEDLE

6 GLOBAL INSULIN PEN NEEDLES MARKET, BY LENGTH
6.1 OVERVIEW
6.2 4MM
6.3 5MM
6.4 6MM
6.5 8MM
6.6 10MM
6.7 12MM

7 GLOBAL INSULIN PEN NEEDLES MARKET, BY THERAPY
7.1 OVERVIEW
7.2 INSULIN
7.3 GROWTH HORMONE
7.4 GLUCAGON-LIKE-PEPTIDE-1 [GLP-1]

8 GLOBAL INSULIN PEN NEEDLES MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 TYPE I DIABETES
8.3 TYPE II DIABETES

9 GLOBAL INSULIN PEN NEEDLES MARKET, BY END-USERS
9.1 HOSPITALS
9.2 HOME HEALTHCARE
9.3 CLINICS
9.4 OTC
9.5 OTHERS

10 GLOBAL INSULIN PEN NEEDLES MARKET, BY GEOGRAPHY
10.1 NORTH AMERICA
10.1.1 MARKET DYNAMICS
10.1.1.1 DRIVERS
10.1.1.2 RESTRAINS
10.1.1.3 OPPORTUNITY
10.1.2 U.S.
10.1.3 CANADA
10.1.4 MEXICO
10.2 EUROPE
10.2.1 MARKET DYNAMICS
10.2.1.1 DRIVERS
10.2.1.2 RESTRAINS
10.2.1.3 OPPORTUNITY
10.2.2 U.K.
10.2.3 FRANCE
10.2.4 GERMANY
10.2.5 SPAIN
10.2.6 REST OF EUROPE
10.3 ASIA PACIFIC
10.3.1 MARKET DYNAMICS
10.3.1.1 DRIVERS
10.3.1.2 RESTRAINS
10.3.1.3 OPPORTUNITY
10.3.2 INDIA
10.3.3 CHINA
10.3.4 JAPAN
10.3.5 REST OF ASIA PACIFIC
10.4 MIDDLE EAST AND AFRICA
10.4.1 MARKET DYNAMICS
10.4.1.1 DRIVERS
10.4.1.2 RESTRAINS
10.4.1.3 OPPORTUNITY
10.4.2 SOUTH AFRICA
10.4.3 REST OF MIDDLE EAST AND AFRICA
10.5 LATIN AMERICA
10.5.1 MARKET DYNAMICS
10.5.1.1 DRIVERS
10.5.1.2 RESTRAINS
10.5.1.3 OPPORTUNITY
10.5.2 BRAZIL
10.5.3 REST OF LATIN AMERICA

11 GLOBAL INSULIN PEN NEEDLES MARKET, BY COMPANY
11.1 INTRODUCTION
11.2 NOVO NORDISK A/S
11.2.1 BUSINESS OVERVIEW
11.2.2 PRODUCTS
11.2.3 KEY STRATEGY
11.2.4 RECENT DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.3 OWEN MUMFORD LIMITED
11.3.1 BUSINESS OVERVIEW
11.3.2 PRODUCTS
11.3.3 KEY STRATEGY
11.3.4 RECENT DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.4 TERUMO CORPORATION
11.4.1 BUSINESS OVERVIEW
11.4.2 PRODUCTS
11.4.3 KEY STRATEGY
11.4.4 RECENT DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.5 MEDEXEL CO.
11.5.1 BUSINESS OVERVIEW
11.5.2 PRODUCTS
11.5.3 KEY STRATEGY
11.5.4 RECENT DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.6 BECTON, DICKINSON, AND COMPANY
11.6.1 BUSINESS OVERVIEW
11.6.2 PRODUCTS
11.6.3 KEY STRATEGY
11.6.4 RECENT DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.7  B BRAUN MELSUNGEN AG
11.7.1 BUSINESS OVERVIEW
11.7.2 PRODUCTS
11.7.3 KEY STRATEGY
11.7.4 RECENT DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.8 ULTIMED INC.
11.8.1 BUSINESS OVERVIEW
11.8.2 PRODUCTS
11.8.3 KEY STRATEGY
11.8.4 RECENT DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.9 YPSOMED HOLDING AG
11.9.1 BUSINESS OVERVIEW
11.9.2 PRODUCTS
11.9.3 KEY STRATEGY
11.9.4 RECENT DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.10  ALLISON MEDICAL, INC.
11.10.1 BUSINESS OVERVIEW
11.10.2 PRODUCTS
11.10.3 KEY STRATEGY
11.10.4 RECENT DEVELOPMENTS
11.10.5 SWOT ANALYSIS